Barclays PLC Boosts Stake in Glaukos Co. (NYSE:GKOS)

Barclays PLC raised its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 394.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 89,699 shares of the medical instruments supplier's stock after buying an additional 71,556 shares during the period. Barclays PLC owned about 0.16% of Glaukos worth $11,686,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Values First Advisors Inc. purchased a new stake in Glaukos during the 3rd quarter valued at $25,000. Harvest Fund Management Co. Ltd raised its stake in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock valued at $117,000 after buying an additional 860 shares during the last quarter. Fifth Third Wealth Advisors LLC purchased a new stake in Glaukos during the 2nd quarter valued at $187,000. KBC Group NV raised its stake in Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock valued at $188,000 after buying an additional 201 shares during the last quarter. Finally, Brighton Jones LLC purchased a new stake in Glaukos during the 2nd quarter valued at $208,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Price Performance

GKOS stock traded up $2.23 during trading on Tuesday, reaching $146.36. The company's stock had a trading volume of 703,556 shares, compared to its average volume of 570,555. Glaukos Co. has a 1 year low of $74.75 and a 1 year high of $147.65. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $8.07 billion, a P/E ratio of -48.46 and a beta of 1.03. The company's fifty day moving average is $136.61 and its 200-day moving average is $127.28.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. During the same quarter in the prior year, the firm earned ($0.50) EPS. The business's revenue was up 23.9% on a year-over-year basis. On average, research analysts expect that Glaukos Co. will post -1.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Glaukos

In related news, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company's stock, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company's stock, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Wall Street Analysts Forecast Growth

GKOS has been the subject of a number of research reports. Piper Sandler set a $140.00 target price on shares of Glaukos in a research note on Thursday, October 17th. Stephens upgraded Glaukos to a "strong-buy" rating in a research note on Monday, December 2nd. StockNews.com upgraded Glaukos from a "sell" rating to a "hold" rating in a research note on Monday, October 21st. BTIG Research upped their price objective on Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Finally, UBS Group initiated coverage on Glaukos in a research note on Friday, December 6th. They issued a "buy" rating and a $182.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and a consensus price target of $143.17.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.